These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 3922294)

  • 21. In vivo postantibiotic effect of isepamicin and other aminoglycosides in a thigh infection model in neutropenic mice.
    Minguez Minguez F; Izquierdo Izquierdo J; Caminero MM; Fuentes Martinez F; Prieto Prieto J
    Chemotherapy; 1992; 38(3):179-84. PubMed ID: 1511635
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative in vitro activity of several antimicrobial agents against selected clinical isolates.
    Liebowitz LD; Saunders J; Chalkley LJ; Koornhof HJ
    S Afr Med J; 1990 Apr; 77(8):395-400. PubMed ID: 2109875
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bactericidal activity of ciprofloxacin in serum and urine against Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumoniae, Staphylococcus aureus and Streptococcus faecalis.
    Lagast H; Husson M; Klastersky J
    J Antimicrob Chemother; 1985 Sep; 16(3):341-7. PubMed ID: 2932416
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Sensitivity of bacteria to netilmicin in comparison with their sensitivity to gentamicin and other aminoglycosides].
    Ruczkowska J; Dolna I
    Przegl Lek; 1988; 45(4):383-6. PubMed ID: 3145533
    [No Abstract]   [Full Text] [Related]  

  • 25. The in vitro activity of netilmicin against 357 clinical isolates of Enterobacteriaceae, Pseudomonas aeruginosa and Staphylococcus aureus.
    Digranes A; Dibb WL; Ostervold B
    Scand J Infect Dis Suppl; 1980; Suppl 23():30-3. PubMed ID: 6782655
    [No Abstract]   [Full Text] [Related]  

  • 26. In vitro pharmacodynamics of piperacillin, piperacillin-tazobactam, and ciprofloxacin alone and in combination against Staphylococcus aureus, Klebsiella pneumoniae, Enterobacter cloacae, and Pseudomonas aeruginosa.
    Hyatt JM; Nix DE; Stratton CW; Schentag JJ
    Antimicrob Agents Chemother; 1995 Aug; 39(8):1711-6. PubMed ID: 7486906
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In-vitro studies of antibiotic combinations with special emphasis on the evaluation of newly developed methods.
    Zinner SH; Blaser J
    J Antimicrob Chemother; 1986 Mar; 17 Suppl A():1-5. PubMed ID: 3086275
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (1997)].
    Ikemoto H; Ito C; Yoshida T; Watanabe K; Mori T; Ohno I; Okada S; Igari J; Arakawa M; Igarashi K; Oguri T; Okada M; Ozaki K; Terai T; Aoki N; Inoue H; Nakadate T; Kitamura N; Sekine O; Suzuki Y; Ando M; Suga M; Sato K; Nakata K; Kusano N
    Jpn J Antibiot; 1999 May; 52(5):353-97. PubMed ID: 10480048
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Susceptibility of 327 clinical isolates to netilmicin.
    Digranes A; Ostervold B; Madsen ST; Solberg CO; Haeger K
    J Int Med Res; 1978; 6(5):409-13. PubMed ID: 100353
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (2000)].
    Shimada K; Terai T; Igari J; Inoue H; Nakadate T; Oguri T; Suwabe A; Obata R; Ikemoto H; Ohno I; Okada S; Hayashi K; Mori T; Nakano K; Arakawa M; Gejyo F; Igarashi K; Yokouchi H; Okada M; Ito A; Sumitomo M; Aoki N; Matsushima T; Niki Y; Kitamura N; Suga M; Suzuki Y; Karasawa Y; Tosaka M; Nakata K; Nakatani T; Kohno S; Tomono K; Miyazaki Y; Inagawa H; Hirakata Y; Aoki S; Matsuda J; Kudo K; Kobayashi N; Kinoshita T; Konosaki H; Nasu M; Nagai H; Kobayashi H; Kawai S; Takayasu S; Hiramatsu K; Nakano T
    Jpn J Antibiot; 2002 Oct; 55(5):537-67. PubMed ID: 12532637
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacodynamics of intermittent- and continuous-infusion cefepime alone and in combination with once-daily tobramycin against Pseudomonas aeruginosa in an in vitro infection model.
    Tessier PR; Nicolau DP; Onyeji CO; Nightingale CH
    Chemotherapy; 1999; 45(4):284-95. PubMed ID: 10394012
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interactions of antimicrobial combinations in vitro: the relativity of synergism.
    Blaser J
    Scand J Infect Dis Suppl; 1990; 74():71-9. PubMed ID: 2129067
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibacterial Properties of Tebipenem Pivoxil Tablet, a New Oral Carbapenem Preparation against a Variety of Pathogenic Bacteria in Vitro and in Vivo.
    Yao Q; Wang J; Cui T; Yang Z; Su M; Zhao P; Yan H; Zhan Y; Yang H
    Molecules; 2016 Jan; 21(1):62. PubMed ID: 26751436
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Experimental pneumococcus infection in mice: correlation of bactericidal activity in vitro with the effect in vivo for gentamicin, netilmicin and tobramycin.
    Frimodt-Møller N; Thomsen VF
    Acta Pathol Microbiol Immunol Scand B; 1987 Jun; 95(3):153-8. PubMed ID: 3630710
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Changes in resistance to aminoglycoside antibiotics of different bacterial strains isolated during the period 1978 to 1983. Netilmicin as alternative therapy.
    Bovelacci A; Montini G; Ramacciotti PG
    Chemioterapia; 1985 Dec; 4(6):439-44. PubMed ID: 3830413
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The in vitro activity of gentamicin, tobramycin and netilmicin against 500 clinical isolates of bacteria. A comparative study using three different test media.
    Digranes A; Dibb WL; Benonisen E; Ostervold B
    Acta Pathol Microbiol Immunol Scand B; 1983 Apr; 91(2):135-9. PubMed ID: 6408889
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Resistance factors: influence on netilmicin activity.
    Kallings LO
    Scand J Infect Dis Suppl; 1980; Suppl 23():54-8. PubMed ID: 6937969
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Once-daily versus thrice-daily administration of netilmicin in combination therapy of Pseudomonas aeruginosa infection in a man-adapted neutropenic animal model.
    Gerber AU; Kozak S; Segessenmann C; Flückiger U; Bangerter T; Greter U
    Eur J Clin Microbiol Infect Dis; 1989 Mar; 8(3):233-7. PubMed ID: 2496992
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics and bactericidal activity of a single daily dose of netilmicin in the treatment of CAPD-associated peritonitis.
    Anding K; Krumme B; Pelz K; Böhler J; Schollmeyer P
    Int J Clin Pharmacol Ther; 1996 Nov; 34(11):465-9. PubMed ID: 8937927
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacodynamics of piperacillin alone and in combination with tazobactam against piperacillin-resistant and -susceptible organisms in an in vitro model of infection.
    Strayer AH; Gilbert DH; Pivarnik P; Medeiros AA; Zinner SH; Dudley MN
    Antimicrob Agents Chemother; 1994 Oct; 38(10):2351-6. PubMed ID: 7840569
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.